铁螯合剂在骨质疏松防治中的应用前景  

Application prospect of iron chelator in the prevention and therapy of osteoporosis

作　　者：赵国阳[1] 徐又佳[2] 

机构地区：[1]江苏大学附属医院骨一科,镇江212001 [2]苏州大学附属第二医院骨科,苏州215004

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2015年第2期164-167,共4页Chinese Journal Of Osteoporosis And Bone Mineral Research

基　　金：国家自然科学基金(81273090);江苏省自然科学基金(BK2012608);镇江市科技计划项目(SH2014031);苏州市社会发展项目(SS201327)

摘　　要：铁过载可导致骨质疏松,降低铁过载的药物有望用于防治伴有铁过载的骨质疏松症。目前临床使用的降低铁过载药物是各种铁鳌合剂,包括去铁胺、去铁酮和地拉罗司。本文总结这3种铁螯合剂临床使用特点,结合其对骨代谢影响实验研究结果,探讨铁鳌合剂作为抗骨质疏松用药的前景。Iron overload may lead to the occurrence and development of osteoporosis, and drug of decreasing i- ron overload may also have clinical potential for osteoporosis patients with iron overload. Currently, the commonly used drugs of decreasing iron are various kinds of iron chelators, which mainly include deferoxamine, deferiprone, and defera- sirox. Here is to summarize the characteristics of three iron chelators, combine with their effects on bone metabolism, and explore their clinical prospect as osteoporosis treatment.

关 键 词：铁过载 铁鳌合剂 骨质疏松 骨代谢 

分 类 号：R681[医药卫生—骨科学]